


CPN

Community Pharmacy News – March 2020



COVID-19 coronavirus

Supporting pharmacy teams to ensure they are well prepared and able to handle the outbreak

CPCF Arrangements for 2020/21 | Prescription endorsements guide

CPCF Arrangements for 2020/21

- Next PQS review point will be in February 2021
- New Discharge Medicines Service and Hep C testing service
- PhIF to be used to pilot additional public health services
- Changes to Terms of Service from July 2020

£2.592bn
overall
funding
which
includes
Transitional
Payments



The arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2020/21 have been agreed between PSNC, NHS England and NHS Improvement (NHSE&I) and the Department of Health and Social Care (DHSC), in line with the five-year CPCF deal.

As set out in the deal, overall funding for community pharmacy will be set at £2.592bn for the year.

There will be an increase in funding for Transitional Payments from April (although these payments will decrease as new services roll out) and the Pharmacy Access Scheme (PhAS) will continue for another year in its current format.

Within the funding envelope a number of new services will be rolled out including an extension of referrals to the Community Pharmacist Consultation Service (CPCS), a new Essential service – the Discharge Medicines Service, and a Hepatitis C testing service. The roll-out of these services is in line with the timetable and agreements made in July 2019.

PSNC, NHSE&I and DHSC have written jointly to contractors today setting out information on the CPCF for 2020/21. The letter sets out as much information as we have at this point in time; remaining details will be announced as soon as possible once Drug Tariff wording has been agreed between the three organisations and when ongoing negotiations on the new services have concluded.

Alongside this, PSNC will work with NHSE&I and DHSC to progress changes that will help contractors to release capacity and make the transition to the new services. The Government is enabling hub and spoke dispensing for all contractors through the Medicines and Medical Devices Bill which has now been published in draft form, and PSNC will be looking to strengthen protections for pharmacies wishing to consolidate and to explore options such as original pack dispensing and facilitating generic substitution of medicines.

PSNC Briefings

The following briefings have been developed to help contractors to better understand the changes that will take place in 2020/21 and how they might affect them.

Community Pharmacy Funding

in 2020/21: This describes how community pharmacy funding will be distributed during 2020/21.

CPCF in 2020/21 – Frequently Asked Questions:

We have compiled a set out of FAQs to help clarify the arrangements for 2020/21.

These briefings, along with full details of the CPCF announcement, can be found at: [ow.ly/eQeq50ytoBp](https://www.ow.ly/eQeq50ytoBp)

Other key changes

Transitional Payments: Increased funding from April 2020, but payments will reduce as the agreed new services come into the CPCF.

Pharmacy Quality Scheme (PQS):

Revised scheme with a new banded payment structure, a single review point in February 2021 and an aspirational payment.

Terms of Service: Expected introduction of new requirements from July 2020.

NHS travel vaccinations: exploratory discussions on the possible introduction of a service.

Pharmacy Integration Fund (PhIF):

monies will be used to begin pilots of pharmacy blood pressure testing, point of care testing and referrals from hospitals to a pharmacy smoking cessation service during 2020/21. And we will continue ongoing work to improve reimbursement for contractors.

Annual review: PSNC has also begun work to prepare for the annual CPCF review process. This review process was agreed as part of the five-year CPCF deal and will be our opportunity to demonstrate the costs and capacity challenges that pharmacy is facing to make the case for further investment in the sector.

COVID-19 update for community pharmacy

Here we provide a round-up of the latest COVID-19 news and guidance for community pharmacy teams. Keep up to date with our dedicated hub: psnc.org.uk/coronavirus

Earlier this month the Government published an action plan detailing how it will handle the potential spread of the COVID-19 coronavirus in the UK.

The plan, developed in response to increasing numbers of cases across the world, builds on observations about the behaviour of similar viruses (e.g. seasonal influenza) and contingency planning from previous outbreaks (e.g. swine flu). It provides the public and business owners with further details of what may happen should COVID-19 become more widespread.

The plan is a high-level document and is supported by further guidance to the NHS, including community pharmacies. Recent updates specific to community pharmacy have been outlined below. Copies of these resources, along with more information, can be downloaded from PSNC's COVID-19 page: psnc.org.uk/coronavirus

Chief Pharmaceutical Officer's letter

The Chief Pharmaceutical Officer, Dr Keith Ridge, wrote to community pharmacies on 9th March 2020. This is the first of a series of regular communications expected in the coming weeks and months.


The letter asks contractors to check their business continuity plans; consider updating any online booking systems; clearly display COVID-19 posters to the public; and read and stay up to date with NHS England and NHS Improvement (NHSE&I) recommendations on the situation.

Guidance for community pharmacy

NHS England and NHS Improvement (NHSE&I) primary care guidance on COVID-19 includes a specific document for community pharmacy teams. The guidance explains how to deal with patients presenting in the pharmacy with suspected COVID-19 infection and preparations contractors can take to deal with such a scenario.

COVID-19 posters

As the COVID-19 coronavirus outbreak continues to have an impact across the world, community



pharmacy contractors have been advised to display PHE posters, so they are visible to people seeking to enter their premises. Please note, these posters were updated on 11th March, and may be altered again as the situation changes..

Personal Protective Equipment (PPE)

Gloves, aprons and face masks should be ordered via normal wholesalers in small quantities for use by pharmacy staff. Public Health England (PHE) is working to ensure that wholesalers' stocks are replenished from the national PHE supplies and free of charge packs of PPEs will be sent to pharmacies in mid-March; these packs will contain 50 masks, 200 aprons and 100 pairs of gloves.

The guidance on use of PPE is still that it **only** needs to be used if you are entering a room in an emergency, where an infected/possibly infected patient is isolated and when decontaminating a room where such a patient has been present (in this case the PPE is to protect the worker from the cleaning products being used). As a consequence of this, the need for community pharmacies to have to use PPE, at this time, is low; the guidance on PPE use will be kept under review as the pandemic progresses.

Preparations for pharmacies

1. Read and implement the NHSE&I guidance;
2. Display the COVID-19 posters at points of entry;
3. Review your business continuity plan;
4. Regularly check the COVID-19 page on GOV.UK and your NHSmail shared mailbox for updates; and
5. Where possible, display the public health advice posters on hand washing etc.

PSNC's work on COVID-19

As the COVID-19 outbreak develops, PSNC has been working closely with HM Government to identify issues and provide support to the community pharmacy sector.



PSNC has commenced detailed discussions with the Department of Health and Social Care (DHSC) and NHS England and NHS Improvement (NHSE&I) to plan for the potential later phases of the COVID-19 outbreak. We are pressing for further support and protection for pharmacies who are already being impacted by the outbreak in the UK.

Matters for discussion have included the provision of protective equipment for pharmacies; contingency funding for any pharmacies who need it; protection for pharmacies against sudden medicines price rises; and ensuring ongoing provision of pharmaceutical services in the case of significant volumes of staff absences. Much of this builds on discussions we have had with the NHS previously about pandemic planning.

We will provide further updates on these matters as soon as we can. Work that is already underway has been outlined below.

National clinical audit cancelled

Following discussions with PSNC, NHSE&I have taken the decision to waive the requirement to complete the National

Antimicrobial Stewardship Clinical Audit for 2019/2020 with immediate effect; at this time NHSE&I instead want to ensure that pharmacies are focused on the actions set out in national communications regarding COVID-19. The audit will now take place in 2020/21; further details on that will be provided later in 2020.

Supply of medicines

As part of their usual work to monitor the supply of medicines, PSNC's Dispensing and Supply Team are keeping a close eye on the generics affected by recent price hikes which have been linked to slow down in output from China and a drug export ban in India. We are and we are in close contact with partners in the supply chain and DHSC, and have commenced discussions with DHSC on protection for pharmacies against sudden price rises.

Some LPCs have flagged local moves by general practices to extend the period of treatment. Following discussions with PSNC about this, NHSE&I and DHSC have issued guidance to practices that this should not happen. If contractors believe that this guidance is not being followed, please immediately raise this with your LPC for further escalation.

Pharmacies have also been asked not to support any patients trying to stockpile.

Community Pharmacy COVID-19 Forum

PSNC has launched the Community Pharmacy COVID-19 Forum, providing an opportunity for information sharing with other pharmacy and supply chain bodies, DHSC and NHSE&I. The group will consider communications to contractors as part of its remit.

Hub page

This is a fast-moving situation, but PSNC has created a page which links to all the latest information, guidance and resources for community pharmacy teams: psnc.org.uk/coronavirus

What PSNC is doing

PSNC is holding discussions with DHSC and NHSE&I on relevant matters and is looking to agree CPCF arrangements that cover circumstances such as:

- Pharmacies having to temporarily close due to COVID-19;
- The temporary re-deployment of pharmacy staff to other community pharmacies or healthcare settings;
- Funding arrangements for any pharmacies which have to close temporarily;
- Cash flow solutions should contractors have to deal with rapidly rising medicines prices;
- Possible community pharmacy support for patients who have to self-isolate due to possible infection or pre-existing conditions which put them at particular risk from infection (this could include delivery of medicines to patients).

Prescription charge increase

The Government has announced an increase to the NHS prescription charge of 15 pence, to **£9.15 per prescription item**. This change will come into effect from 1st April 2020.

The cost of prescription pre-payment certificates (PPCs) will increase to £29.65 for a three-month PPC and £105.90 for a 12-month PPC.

PSNC has published a Prescription Charge Card for display in community pharmacies, which is now available on the PSNC website.

Download your copy from psnc.org.uk/chargecard

Changes to FP10 forms

Community pharmacy teams may now be starting to see the new FP10 forms/tokens, which include important changes to the reverse of all FP10 prescription form types (FP10SS, FP10D, FP10PN, etc.).

To help explain the differences between the existing and new forms, PSNC has produced a list of FAQs to be read in conjunction with guidance produced by the Department of Health and Social Care and the NHS Business Services Authority.

Read the FAQs at: ow.ly/UcYl30qp0Re

Can you help with RTEC piloting?

System suppliers are seeking community pharmacy contractor volunteers to take part in Real Time Exemption Checking (RTEC) piloting. This follows the announcement that RTEC is due to be piloted and rolled out across more pharmacy patient medication record (PMR) systems.

Participation in the pilot will provide you with an opportunity to provide feedback directly to your PMR supplier and other stakeholders (which could include the NHS Business Services Authority, PSNC and NHS Digital) about how the RTEC feature might best work for your pharmacy team.

Find out more at: ow.ly/bBLs50yHPmt

SSP issued for Fluoxetine 10mg tablets

A Serious Shortage Protocol (SSP) was introduced for Fluoxetine in March 2020. It requires the following action to be taken by pharmacy teams.

“Enabling community pharmacists to substitute one formulation for another”



In response to significant ongoing disruption to the supply of Fluoxetine 10mg tablets, an SSP was issued by the Department of Health and Social Care (DHSC) on 12th March 2020.

The protocol, SSP05, has been developed by clinicians and provides pharmacists with procedures to follow in providing a suitable alternative product, Fluoxetine 10mg capsules in response to the serious shortage affecting the tablets. It has been authorised by the Secretary of State to help manage the supply of this product and to try to ensure that fewer patients have to return to their prescriber.

Community pharmacy contractors and their teams are asked to read the document below in full and to implement the protocol with immediate effect on Thursday 12th March 2020.

The SSP provides that the capsule formulation of Fluoxetine may be supplied against prescriptions for Fluoxetine 10mg tablets as follows:

For prescriptions (NHS or private) requesting:	Supply permitted under SSP05:
Fluoxetine 10mg tablets	Fluoxetine 10mg capsules

SSP05 is currently due to expire on Friday 12th June 2020, but it could be amended or revoked at any time. PSNC will update contractors about any changes via our usual communication channels.

Action to take

In preparation:

- Review the relevant SSP documents
- PSNC Briefing 015/20: Serious Shortage Protocols (SSPs): SSP05 – Fluoxetine 10mg tablets at: psnc.org.uk/SSPbriefing

When presented with a prescription for this drug:

- Check the protocol is still in place at: psnc.org.uk/liveSSPs
- Follow the protocol whilst remembering that the pharmacist must exercise their professional judgement to ensure the alternative product is suitable for the patient.

Pharmacy notice board

In this section of Community Pharmacy News we have highlighted some key notices for you and your team to be aware of in the coming weeks and months.



PSNC website: your picks

More than 2.3 million people visited the PSNC website in 2018/19, but what keeps them coming back? In February 2020:

Average visitors per day: 7,545

Most popular news story:
CPCF Negotiations Progress Update and Arrangements for 2020/21

Most popular PSNC Briefing:
004/20: Pharmacy Quality Scheme - Completing your declaration

Most popular search terms:
PQS, MUR, essential services, audit, NMS



Flu vaccines for 2020/21



Patients 65 and over - adjuvanted trivalent vaccine (aTIV) is the recommended vaccine for this group, but quadrivalent influenza cell-culture vaccine (QIVc) can be offered if aTIV is not available.

Patients 18-64 in an at-risk group - QIVc is the recommended vaccine, but quadrivalent influenza egg-culture vaccine (QIVe) can be offered if QIVc is not available.

Read the NHS advice at:
[ow.ly/5tGt30qnKLLk](https://www.nhs.uk/health-a-z/flu-vaccines/flu-vaccines-for-2020-21/)



Supply updates

Diamorphine Hydrochloride powder for reconstitution and injection 5mg and 10mg ampoules
Accord are out of stock of both strengths with a resupply date of summer 2020. Wockhardt are expecting to be out of stock until w/c 6th April 2020.

H2-antagonists (Cimetidine and Nizatidine)
Cimetidine 200mg tablets are out of stock until the end of March 2020 (Ennogen) and May 2020 (Medley Pharma).

Nizatidine 150mg and 300mg tablets: No confirmed resupply date (Medreich and Mylan).

Mesalazine (Salofalk) suppositories (500mg and 1g)
Resupply date now expected mid-April 2020 for the 500mg suppositories, mid-September 2020 for the 1g suppositories.

Phenytoin (Epanutin®) 30mg/5ml oral suspension
Re-supply date late June 2020.

Penicillamine 125mg tablets
Re-supply date late March 2020.

Salbutamol 2mg/5ml syrup
Resupply date now expected end of March 2020.

Valproate semisodium (Depakote) 250mg and 500mg tablets
Re-supply date early April 2020.

Visit the PSNC website for more details.



Ask PSNC


The PSNC Dispensing and Supply Team can provide community pharmacy teams with support and advice on a range of topics related to the Drug Tariff and reimbursement. Questions asked in recent months include:



Q. Can EPS prescriptions be issued for an item endorsed with the 'FS' for free supply of sexual health treatment?

A. No. The new prescriber endorsement 'FS' is not yet configured into prescribing systems and the changes are being made as soon as possible. Once prescribing systems have been updated pharmacy teams can expect their EPS systems to display the 'FS' endorsement in a similar way to the 'AF' endorsement for assorted flavours. If a prescriber adds supplementary information such as 'FS' into another field (for example as part of the dosage instructions) and that 'changes the prescribed product', this will not be taken into account for reimbursement purposes as this information is not captured by the NHS Business Services Authority (NHSBSA) during processing. Prescribers must not add 'free text' to any other fields for example dosage instructions or 'additional instructions' also known as medication specific information or notes to Pharmacy. If you are unsure how 'FS' will be displayed on your EPS system please contact your system supplier for information.

Until selection of 'FS' endorsement has been enabled in prescribing systems, prescribers should revert to issuing paper prescriptions with 'FS' manually endorsed next to each item intended for the treatment of an STI. Where 'FS' has been added as a handwritten endorsement, for example, on a computer-generated form, this should be counter-signed in the usual way.



Q. I have received a prescription requesting 'Levothyroxine Sodium 100mcg tablets (Actavis UK)'. Do I have to dispense the Actavis brand and what will I be reimbursed for?

A. When a prescription requesting generic 'Levothyroxine 100 mcg tablets' is received, a pharmacist can dispense any brand and will be reimbursed according to the Drug Tariff Part VIII price for the product.

However, where a prescription specifies the name of a manufacturer or supplier, legally and ethically that manufacturer's product must be dispensed, and the pharmacist would be reimbursed based on the manufacturer or supplier's list price. Out of pocket expenses in procuring the product may be claimed, where appropriate (see: psnc.org.uk/oop)

PSNC has received a number of reports of GPs inadvertently issuing prescriptions in this way because of the way products are listed in the picking-list of their prescribing system. This practice is not in the interests of patients, the NHS or community pharmacies as it could lead to increased prescribing costs and delays for patients. If contractors identify this as an issue in a locality, this is something that should be discussed with the prescriber.



Q. I have a prescription for 'Phenytoin 30mg/5ml Oral Suspension' but am only able to obtain an unlicensed special due to a shortage, will I be paid for it?

A. No. The prescription must state 'Phenytoin 30mg/5ml Oral Suspension (Special Order)' to ensure community pharmacy contractors are paid for an unlicensed special. There is currently no listing on the NHS Dictionary of Medicines and Devices (dm+d) for the imported product so, where a prescriber wishes to prescribe an unlicensed import, a paper prescription should be issued specifying a 'special order' and then endorsed with the following:

- Amount dispensed over pack size used;
- Invoice price per pack size from which the order was supplied less any discount or rebate;
- Manufacturer's/importer's MHRA licence number;
- Batch number of the product supplied; and
- SP.

Contractors are also reminded that all prescriptions for unlicensed medicines should be placed in the red separators for your end of month submission. For more information on unlicensed specials and imports, see: psnc.org.uk/unlicensed

Dispensing Factsheet: Prescription endorsements

This is a quick reference guide to the prescription endorsements which pharmacy teams may need to use. Accurate endorsement is vital to ensuring correct payment from the Pricing Authority.

1. General endorsements – The guidance below is intended as a quick reference only.

Prescribed item	Required endorsement
A generic medicine listed in Part VIIIA of the Drug Tariff.	For Part VIIIA products, the only endorsement required is the pack size where there are multiple pack sizes listed.
A generic medicine listed in Part VIIIB of the Drug Tariff.	There is no endorsement required for Part VIIIB listed products (apart from claiming the sourcing fee with "SP" or "ED", where appropriate).
A generic medicine which is not listed in Part VIIIA of the Drug Tariff.	Endorse with the brand name or manufacturer/supplier as well as pack size where there are multiple pack sizes available. If the product does not have a price listed in the Dictionary of Medicines and Devices (dm+d) ¹ , the net price before discount and exc. VAT should also be endorsed.
An unlicensed medicine (or special) which is not listed in Part VIIIB of the Drug Tariff and has been sourced under a manufacturer's specials/importer's licence ² issued by the MHRA.	Endorse: <ul style="list-style-type: none"> • Amount dispensed over pack size used; • Invoice price per pack size from which the order was supplied <i>less</i> any discount or rebate; • Manufacturers'/ importers' MHRA license number; • Batch number of the product supplied; • SP (for costs incurred in obtaining the item) <i>(more information at: psnc.org.uk/specials)</i>
An unlicensed medicine (or special) which is not listed in Part VIIIB and has been manufactured under the Section 10 exemption from the Medicines Act 1968 (either by the contractor or a third party).	Endorse the names, quantities and cost of the ingredients used in preparing the product plus "ED" for costs incurred in dispensing a product prepared under the Section 10 exemption (<i>more information at: psnc.org.uk/specials</i>).
A branded medicine.	The only endorsement required is the pack size. If the product does not have a price listed in the dm+d, the net price before discount and excluding VAT should also be endorsed.
A generic appliance which is only listed generically in Part IX of the Drug Tariff.	The only endorsement required is the pack size where multiple pack sizes are available. Additionally, ensure elastic hosiery prescriptions indicate: <ul style="list-style-type: none"> • the total quantity to be supplied; • a description of the article (e.g. circular knit, below knee); • the compression class
A generic appliance which is listed by brand or manufacturer in Part IX of the Drug Tariff.	Endorse with a brand or manufacturer's name as listed in the Tariff. Only endorse the pack size where there are multiple pack sizes listed in the Tariff. Please note: some appliances have default prices, listed at the beginning of the relevant Drug Tariff section, which are used for pricing in this situation. These are: catheters, elasticated tubular bandages, absorbent perforated plastic film faced dressings, permeable non-woven synthetic adhesive tape BP 1988, and peak flow meters. To be reimbursed for any of the above products which may be priced higher than the default price, the prescription must be returned to the prescriber for amendment to include a specific brand name as listed in the Drug Tariff.
A branded appliance which is listed by brand or manufacturer in Part IX of the Drug Tariff.	The only endorsement required is pack size where there are multiple pack sizes listed.

1. The Dictionary of Medicines and Devices is the database used by the NHS to standardise the language used to describe medicines within the NHS. This database also contains information regarding the price of medicines. Pharmacy staff can access this database by visiting <https://apps.nhsbsa.nhs.uk/DMDBrowser/DMDBrowser.do>

2. The manufacturer's specials/importer's license number can be found on the invoice or CoC/CoA for the product.

2. Specific endorsements

Below are the most commonly used endorsements, but pharmacy staff will need to check for an item's eligibility.

Category	Endorsement
Broken Bulk	"BB" and amount dispensed over pack size used (<i>more information at: psnc.org.uk/bb</i>).
Extemporaneously Dispensed	"ED" (<i>more information at: psnc.org.uk/specials</i>).
Hosiery	Compression class, article style, quantity, knit, "made to measure" if appropriate.
Instalment Dispensing	Date, quantity, pharmacist initials for each instalment (<i>more information at: psnc.org.uk/mda</i>).
Measured and Fitted	"MF"
Not Dispensed	"ND" and score through the item in the prescribing area.
Out of Pocket Expenses	"OOP" on paper prescriptions or "XP" on EPSR2 prescription, name or description of the charge, price paid (<i>more information at: psnc.org.uk/ooop</i>).
Packaged Doses (for oral liquid methadone)	"PD" followed by the number of additional doses packaged separately (<i>more information at: psnc.org.uk/methadone</i>).
Prescriber Contacted	"PC" and the missing information, date and initials.
Prescriber Not Contacted	"PNC" and the missing information, date and initials.
Serious Shortage Protocols (SSPs)	"NCSO" and the following information <ul style="list-style-type: none"> • Details of product supplied in accordance with the SSP (drug name, quantity, strength, formulation, supplier name or brand)*; • Quantity supplied*; • Pack size – best practice where multiple pack sizes are available; and • Invoice price – only if NHSBSA has no list-price available on dm+d. * <i>The drug details and quantity supplied and endorsed will depend on the specific SSP</i>
Trusses	Single or double, position, type.
Unlicensed Specials and Imports	"SP" (<i>more information at: psnc.org.uk/specials</i>).

3. Prescriber endorsements

Below is a list of the endorsements which only a prescriber can add to a prescription item.

Endorsement	What it means for dispensing
ACBS	<i>No impact on dispensing.</i> If an item which is found on the Borderline Substances list (Part XV of DT) has not been endorsed by the prescriber, this product can still be dispensed as it isn't a compulsory requirement (but the prescriber may be questioned by the Area Team later).
FS	<i>No patient charge is payable for this item.</i> FS enables prescribers to endorse prescriptions for STIs to indicate to dispensers that the patient should not be charged. The FS endorsement should not be manually added to the EPS dosage instructions field as this would not allow a pharmacy to supply any treatment for STIs free-of-charge against NHS prescriptions.
SLS	<i>If required, this endorsement must have been made by the prescriber before dispensing.</i> If a medicine which is found in the Selected List Scheme (Part XVIII of DT) has not been endorsed by the prescriber, the prescription would need to be returned to the prescriber for amendment – pharmacy staff cannot make this endorsement themselves.
Either "OC", "CC" or "♀"	<i>No patient charge is payable for this item.</i> This endorsement is the prescriber declaring that it is to be used for contraceptive purposes.
Bulk Prescription	<i>No patient charge is payable for this item.</i> This endorsement is the prescriber declaring that the criteria for issuing bulk prescriptions have been met.

For the most up to date information on endorsements, please visit: psnc.org.uk/endorsement

Drug Tariff Watch

The Preface lists additions, deletions and alterations to the Drug Tariff. Below is a quick summary of the changes due to take place from **1st April 2020**.

KEY:

- Special container
- * This pack only (others already available)
- SLS Selected List Scheme

Part VIII A additions

Category C:

- **SLS** Alprostadil 10microgram powder and solvent for solution for injection cartridges ■ (2) – *Viridal Duo Continuation Pack*
- Chenodeoxycholic acid 250mg capsules (100) – *Leadiant Biosciences Ltd*
- Liothyronine 10microgram tablets 28 – *Morningside Healthcare Ltd*
- Liothyronine 20microgram powder for solution for injection vials (5) – *Advanz Pharma*
- Liothyronine 5microgram tablets (28) – *Morningside Healthcare Ltd*
- Pneumococcal polysaccharide conjugated vaccine (adsorbed) suspension for injection 0.5ml pre-filled syringes ■ (1) – *Prevenar 13*
- Posaconazole 40mg/ml oral suspension (105ml) – *Noxafil*

Part VIII A amendments

- Bimatoprost 100micrograms/ml eye drops ■ (3ml) *Lumigan* is moving to Category A
- Diclofenac sodium 100mg modified-release tablets (28) *Fenactol Retard* is changing reference product to *Dicloflex Retard*

Part VIII A deletions

- Minocycline 50mg capsules (56) – *Aknemin 50*
- Octreotide 50micrograms/1ml solution for injection vials (5) – *Pfizer Ltd*
- Tramadol 75mg modified-release tablets (60) – *Zytram SR*
- Tramadol 75mg / Paracetamol 650mg tablets (30) – *Aspire Pharma Ltd*

Part IX deletions

It is important to take careful note of removals from Part IX because if you dispense a deleted product, prescriptions will be returned as disallowed and therefore payment will not be made for dispensing the item.

Product	Additional information (e.g. size, product code, etc.)
ANAL IRRIGATION SYSTEM – Aquaflush Quick System – Starter Set (Contains 1 water bag, 1 pump, 1 hook for water bag, 1 extension tube, 5 cones, 5 glove/disposal bags, 1 strap, 1 washbag)	AFQS
CATHETERS, URINARY, URETHRAL – Nélaton Catheter ('ordinary' cylindrical Catheter) Single use – Covidien UK Commercial Ltd – VaQua	All types and sizes
CATHETERS, URINARY, URETHRAL – Foley Catheter – 2 Way For Long Term Use – Adult – Covidien UK Commercial Ltd – Dover All Silicone – Female	All sizes
CATHETERS, URINARY, URETHRAL – Foley Catheter – 2 Way For Long Term Use – Adult – Covidien UK Commercial Ltd – Ultramer	All types and sizes
WOUND MANAGEMENT DRESSINGS – Ultec Pro	All types and sizes
EMOLLIENT AND BARRIER PREPARATIONS – Epimax Paraffin-Free Cream	500g
INCONTINENCE APPLIANCES – INCONTINENCE SHEATHS – Covidien UK Commercial Ltd – Texas Catheter (including adhesive strip)	8884731300
INCONTINENCE APPLIANCES – TUBING AND ACCESSORIES – Covidien UK Commercial Ltd – Argyle Penrose Tubing	All types and sizes
STOMA APPLIANCES – BELTS – Salts Healthcare – 102mm Elastic Belt with waterproof panel with 4 loops & retaining ring	877009
STOMA APPLIANCES – COLOSTOMY BAGS – Hollister Ltd – Impression "C" with convex wafer Beige with filter and beige Comfort backing on both sides	19mm (3490) and 38mm (3496)
STOMA APPLIANCES – ILEOSTOMY (DRAINABLE) BAGS – ConvaTec Ltd – Ileodress Plus – with modified Stomahesive wafer, perforated plastic backing and beige clip pouches – Small Size – Opaque	19mm starter hole (S430)
STOMA APPLIANCES – ILEOSTOMY (DRAINABLE) BAGS – Dansac Ltd – Dansac NovaLife TRE 1 open convex – Maxi cut-to-fit	15-59mm (3042-59)
STOMA APPLIANCES – ILEOSTOMY (DRAINABLE) BAGS – Hollister Ltd – Impression with Convex wafer Transparent	38mm (3616) 41mm (3617)
STOMA APPLIANCES – ILEOSTOMY (DRAINABLE) BAGS – Hollister Ltd – Premium with integral filter holder and twenty replacement filters	64mm (3665)

PSNC resources library

In this section of Community Pharmacy News we have provided details of some of the resources that PSNC has produced this month.



PSNC Briefings



PSNC Briefing 006/20: An update about Patient Facing Services ('online services') and other app offerings

An update for community pharmacy contractors and Local Pharmaceutical Committees (LPCs) about Patient Facing Services being provided via NHS / GP IT systems, as well as an update about patient apps offerings.

Download from: ow.ly/lkCt30qniIL



PSNC Briefing 008/20: Changes to the GP contract in 2020/21

A summary of the changes to the General Medical Services (GMS) contract in 2020/21 which are of most relevance to community pharmacy, including LPC officers and members and Primary Care Network (PCN) pharmacy leads.

Download from: ow.ly/cijE30qniEE



PSNC Briefing 012/20: The national data opt-out system, and how to complete the DSPTK opt-out question

This PSNC Briefing explains what the national data opt-out system for patients is and how community pharmacy contractors can complete the Data and Security Protection Toolkit question about the data opt-out system.

Download from: ow.ly/rNJG30qniDc

See all our PSNC Briefings in our database at: psnc.org.uk/briefings



Other resources



Consolidations and mergers webinar on-demand

This webinar aims to support community pharmacy contractors who may be considering consolidating or merging two or more pharmacies or pharmacy businesses, but may also be useful for LPCs who often support contractors with pharmacy applications.

Watch now: psnc.org.uk/mergerswebinar

Look out for additional resources as you explore our website: psnc.org.uk



Email news alerts



CPCF Negotiations Progress Update and Arrangements for 2020/21 (23rd February)

Announcing the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2020/21. Key elements include an increase in funding for Transitional Payments from April and the introduction of a Discharge Medicines Service.

Read now: ow.ly/FFK230qnjhr



COVID-19: An update for community pharmacy (4th March)

Highlighting the Government's action plan for handling COVID-19, noting that PSNC has commenced discussions with DHSC on how an outbreak may affect pharmacies, and outlining next steps for pharmacy teams.

Read now: ow.ly/ES0030qnjXA

Not receiving our emails? Sign up now at: psnc.org.uk/enews